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We appreciate the comments of Donna Graham et  al. on our 
recent article (1). The first issue they raise concerns the use of an 
adjuvant treated patient cohort for risk scores intended to assist 
in decisions regarding whether or not such treatment should be 
administered at all. While we agree with this perception, we also 
contend that prognostic signatures so far have failed to provide 
information on likelihood of response to drugs in the adjuvant 
setting, which implies that they represent inherent prognos-
tic groups, the outcome of which is not improved by therapy. 
This is an issue in itself, but beyond the scope of our paper. In 
absence of such evidence, a treated patient cohort is potentially 
as informative on the prognostic groups.
The second issue is the low number of stage II patients in 
our cohort. We agree that risk scores will be most informative in 
stage II patients. However, we consider a search for a very low 
risk subgroup in stage III colon cancer equally relevant, nota-
bly as we found evidence that such a subgroup likely exists (2). 
Furthermore, we currently ignore if genes making up relevant 
prognostic risk scores for stage II and stage III are the same, as 
was suggested in one study (3), or different. This is an additional 
justification of including stage III in an assessment of the clini-
cal relevance of risk scores.
The third issue raised is the purported basis of our analy-
sis on splitting the continuous score at the median. This state-
ment is inaccurate as in fact the main analyses were done with 
continuous scores in survival regression (Table 2) and in time-
dependent area under the curve analyses (Table  5). Median 
splits were only used for a Kaplan-Meier analysis (Table 3). As 
the PETACC III gene expression data were obtained using the 
same array platform as the ColDx risk score, a predefined cut-
off might be meaningful. However, the other risk scores are not 
on the original scales. Incidentally, the advantage of an analysis 
based on a continuous score is that it generally summarizes well 
the prognostic information of a marker, and results do not show 
the typical large fluctuation seen with specific splits (unless the 
cohort would be very large) that can render statistically robust 
interpretations more difficult.
Regarding the comment on the general applicability of prog-
nostic signatures for clinical practice, we reemphasize the key 
(and disturbing) message of our study: Application of four risk 
scores yielded contradictory assessment of low or high risk at 
the level of the individual patient because of poor correlation 
of genes in the respective signatures. This message is likely to 
be generally valid, also in gene expression profiles of stage II 
patients. We agree with Donna Graham et al. that robust prog-
nostic scores are needed, and we appreciate their efforts to 
produce or test them. Our results suggest that such prognostic 
scores in colon cancer are more difficult to find than has been 
the case in breast cancer, where different groups quickly con-
verged on concordant systems with proliferation markers as 
dominant component (4).
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